William Blair upgraded shares of Quintiles Transitional Holdings Inc. (NYSE:Q) from a market perform rating to an outperform rating in a research note issued to investors on Friday, MarketBeat reports. William Blair currently has $93.42 target price on the medical research company’s stock, up from their prior target price of $70.10. William Blair also issued estimates for Quintiles Transitional Holdings’ Q4 2017 earnings at $1.34 EPS, FY2017 earnings at $4.57 EPS, FY2018 earnings at $5.31 EPS and FY2019 earnings at $6.03 EPS.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Quintiles Transitional Holdings from a buy rating to a hold rating in a research report on Tuesday, August 1st. Barclays PLC restated an overweight rating and issued a $98.00 price target (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research report on Monday, July 17th. Robert W. Baird upgraded Quintiles Transitional Holdings from an underperform rating to a neutral rating and boosted their price target for the company from $76.00 to $93.00 in a research report on Friday, July 7th. Citigroup Inc. restated a neutral rating and issued a $96.00 price target (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research report on Wednesday, June 28th. Finally, Credit Suisse Group restated an outperform rating and issued a $96.00 price target (up previously from $94.00) on shares of Quintiles Transitional Holdings in a research report on Tuesday, June 6th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Quintiles Transitional Holdings has an average rating of Hold and an average target price of $89.88.

Quintiles Transitional Holdings (NYSE Q) traded up 0.94% during mid-day trading on Friday, reaching $91.27. The company had a trading volume of 870,803 shares. Quintiles Transitional Holdings has a 12 month low of $70.10 and a 12 month high of $92.54. The company has a market capitalization of $20.08 billion, a price-to-earnings ratio of 201.92 and a beta of 0.64. The firm’s 50 day moving average price is $89.50 and its 200-day moving average price is $82.85.

Quintiles Transitional Holdings (NYSE:Q) last posted its earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a return on equity of 15.68% and a net margin of 0.82%. The business had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same period in the previous year, the business earned $0.93 EPS. The business’s quarterly revenue was up 68.7% on a year-over-year basis. Equities research analysts anticipate that Quintiles Transitional Holdings will post $4.57 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Quintiles Transitional Holdings Inc. (NYSE:Q) Upgraded by William Blair to “Outperform”” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/quintiles-transitional-holdings-inc-nyseq-upgraded-by-william-blair-to-outperform.html.

Quintiles Transitional Holdings announced that its board has authorized a share repurchase program on Wednesday, May 24th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 5.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

In related news, Director John G. Danhakl sold 761,143 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $84.01, for a total value of $63,943,623.43. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Cpp Investment Board Private H sold 7,131,165 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $84.01, for a total value of $599,089,171.65. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,758,400 shares of company stock worth $735,783,985. Insiders own 6.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Quintiles Transitional Holdings by 4,217.1% in the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock worth $571,660,000 after buying an additional 6,934,290 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in Quintiles Transitional Holdings by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 49,056 shares of the medical research company’s stock worth $3,950,000 after buying an additional 545 shares in the last quarter. WCM Investment Management CA boosted its stake in Quintiles Transitional Holdings by 0.3% in the first quarter. WCM Investment Management CA now owns 558,238 shares of the medical research company’s stock worth $44,955,000 after buying an additional 1,803 shares in the last quarter. Creative Planning boosted its stake in Quintiles Transitional Holdings by 35.4% in the first quarter. Creative Planning now owns 4,482 shares of the medical research company’s stock worth $361,000 after buying an additional 1,172 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in Quintiles Transitional Holdings by 31.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 22,313 shares of the medical research company’s stock worth $1,797,000 after buying an additional 5,340 shares in the last quarter. Institutional investors and hedge funds own 91.83% of the company’s stock.

About Quintiles Transitional Holdings

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.